LeonaBio, Inc. (LONA): who owns it and who trades it
As of Nov 16, 2026, LONA insiders reported 9 open-market sales worth $93.4K and no purchases in the last 12 months, with 0% of the sale value made under pre-set 10b5-1 plans. The largest seller was Mark James Litton (CEO), with $45.5K. 3 of the 50 famous funds we follow held it at their last quarter end.
Latest filing Nov 16, 2026. From Form 4, 13F and Schedule 13D/G filings.
At a glance
Who is buying and selling LeonaBio
From the latest filingsOverall: more selling than buying. Insiders and famous investors mostly sold. Funds mostly bought.
Each group counts equally in the meter, by the number of buyers and sellers, not dollars. Insider sales under pre-set 10b5-1 plans are left out of it. From SEC, House and Senate filings; not advice.
Who owns LONA
44 funds and institutions reported LONA shares worth $70.4M at the end of Q2 2026, about 82% of the company. The largest holder is Perceptive Advisors LLC with 19.8%.
Funds and institutions (13F) 82%Everyone else 18%
10 largest owners, by share of the company
Top 20 owners
| Owner | Shares | % of company | Value | Change since Q1 2026 |
|---|---|---|---|---|
| Perceptive Advisors LLC | 1.86M | 19.79% | $17.1M | No change |
| Kalehua Capital Management LLC | 787,402 | 8.38% | $7.2M | No change |
| ADAR1 Capital Management, LLC | 777,100 | 8.27% | $7.1M | +7% |
| Acorn Capital Advisors, LLC | 634,539 | 6.76% | $5.8M | No change |
| NEA Management Company, LLC | 464,398 | 4.94% | $4.3M | No change |
| Commodore Capital LP | 464,398 | 4.94% | $4.3M | No change |
| TCG Crossover Management, LLC | 464,398 | 4.94% | $4.3M | No change |
| Spruce Street Capital LP | 393,701 | 4.19% | $3.6M | No change |
| Blackstone Inc. | 324,638 | 3.46% | $3M | New |
| Adage Capital Partners Gp, L.l.c. | 300,000 | 3.19% | $2.8M | New |
| Vanguard Capital Management LLC | 275,233 | 2.93% | $2.5M | +41% |
| Seven Fleet Capital Management LP | 154,153 | 1.64% | $1.4M | -6% |
| Propel Bio Management, LLC | 149,279 | 1.59% | $1.4M | No change |
| Simplify Asset Management Inc. | 149,279 | 1.59% | $1.4M | No change |
| Geode Capital Management, LLC | 80,418 | 0.86% | $740K | +0% |
| BlackRock, Inc. | 79,186 | 0.84% | $728K | +41% |
| Renaissance Technologies LLC | 77,424 | 0.82% | $712K | +21% |
| Vanguard Fiduciary Trust Co | 42,814 | 0.46% | $393K | +7% |
| Bank of America Corp | 32,557 | 0.35% | $299K | No change |
| Millennium Management LLC | 32,450 | 0.35% | $298K | +2% |
From the SEC 13F data sets: every fund manager with over $100M must report its US stock holdings every 3 months, up to 45 days after the quarter ends. Owners are shown as they file, so one group (for example Vanguard) can appear under several names. Individuals, most insiders and smaller funds do not file 13F reports.
Insider trades
In the last 12 months, LONA insiders reported $0 of open-market purchases and $93.4K of sales. 0% of the sale value was under a 10b5-1 plan, a schedule set up in advance.
Purchases and sales by month
Latest trades
| Date | Insider | Role | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|---|
| Mar 4, 2026 | Mark James Litton | CEO | Sale | 5,156 | $5.37 | $27.7K | Form 4 |
| Mar 4, 2026 | Robert Renninger | CFO | Sale | 906 | $5.37 | $4.9K | Form 4 |
| Mar 4, 2026 | Mark Worthington | GENERAL COUNSEL and CCO | Sale | 1,328 | $5.37 | $7.1K | Form 4 |
| Mar 4, 2026 | Kevin Church | CHIEF SCIENTIFIC OFFICER | Sale | 1,359 | $5.37 | $7.3K | Form 4 |
| Mar 4, 2026 | Martin Javier San | CHIEF MEDICAL OFFICER | Sale | 1,720 | $5.37 | $9.2K | Form 4 |
| Jan 2, 2026 | Martin Javier San | CHIEF MEDICAL OFFICER | Sale | 1,644 | $6.88 | $11.3K | Form 4 |
| Jan 2, 2026 | Mark James Litton | CEO | Sale | 2,586 | $6.88 | $17.8K | Form 4 |
| Jan 2, 2026 | Robert Renninger | CFO | Sale | 297 | $6.88 | $2K | Form 4 |
| Jan 2, 2026 | Kevin Church | CHIEF SCIENTIFIC OFFICER | Sale | 876 | $6.88 | $6K | Form 4 |
Insiders by value traded
| Insider | Role | Bought | Sold | Last trade |
|---|---|---|---|---|
| Mark James Litton | President and CEO, Director | – | $45.5K | Mar 4, 2026 |
| Martin Javier San | CHIEF MEDICAL OFFICER | – | $20.5K | Mar 4, 2026 |
| Kevin Church | CHIEF SCIENTIFIC OFFICER | – | $13.3K | Mar 4, 2026 |
| Mark Worthington | GENERAL COUNSEL and CCO | – | $7.1K | Mar 4, 2026 |
| Robert Renninger | Chief Financial Officer | – | $6.9K | Mar 4, 2026 |
What this data shows, and what it doesn't
- Shows: open-market purchases and sales by officers, directors and 10%+ owners, reported on Form 4 within two business days of the trade.
- Leaves out: stock awards, option exercises, shares withheld for tax and gifts. These are not trades at a market price chosen by the insider.
- "plan" marks a sale made under a Rule 10b5-1 plan, a schedule set up in advance.
- Fund holders come from 13F reports, a snapshot at quarter end filed up to 45 days later.
- Filings are self-reported and can be amended. Each trade links to its original filing. Methodology
LONA short interest
Low short interest. 0.8% of LONA shares are sold short: about 1 share in 126. Over the last 12 reports the number of shares short went up 20%.
As a rough guide, under 5% is low, 5–10% is moderate, 10–20% is high and over 20% is very high.
As of Oct 30, 2026, 74,491 LONA shares were sold short, 0.8% of the shares outstanding, down 14.7% from the report before. At the average daily volume of 65,795 shares, buying them all back would take about 1.1 trading days (days to cover).
Shares short, % of all shares
Days to cover
Every report
| Settlement date | Shares short | % of shares | Change | Avg daily volume | Days to cover |
|---|---|---|---|---|---|
| Oct 30, 2026 | 74,491 | 0.79% | -15% | 65,795 | 1.1 |
| Oct 15, 2026 | 87,344 | 0.93% | +356% | 726,433 | 1.0 |
| Sep 30, 2026 | 19,166 | 0.20% | -19% | 192,321 | 1.0 |
| Sep 15, 2026 | 23,651 | 0.25% | -41% | 64,689 | 1.0 |
| Aug 31, 2026 | 40,293 | 0.43% | +3% | 82,813 | 1.0 |
| Aug 14, 2026 | 38,973 | 0.41% | -4% | 11,137 | 3.5 |
| Jul 31, 2026 | 40,714 | 0.43% | -25% | 20,484 | 2.0 |
| Jul 15, 2026 | 53,976 | 0.57% | -4% | 57,290 | 1.0 |
| Jun 30, 2026 | 56,070 | 0.60% | +9% | 19,036 | 3.0 |
| Jun 15, 2026 | 51,630 | 0.55% | -9% | 17,591 | 2.9 |
| May 29, 2026 | 56,592 | 0.60% | -9% | 48,780 | 1.2 |
| May 15, 2026 | 61,955 | 0.66% | +7% | 37,440 | 1.6 |
Short sellers borrow shares and sell them, hoping to buy them back for less. A high number means many such bets are open. It does not say where the price will go. Source: FINRA equity short interest, reported by brokers twice a month (positions on the 15th and the last business day) and published about 7 business days later. % of shares uses the share count on the company's latest SEC filing. What short interest means · Most shorted stocks
LeonaBio company events
LeonaBio filed 11 reports on Form 8-K in the last 12 months, 2 of them about an important change (leadership). The latest was on Sep 22, 2026.
- Sep 22, 2026AnnouncementIn December 2025, as part of a private placement, LeonaBio, Inc. issued warrants to purchase an aggregate of 23,031,494 shares of its common stock. Filing
- Aug 26, 2026AnnouncementLeonaBio, Inc. announced that it had enrolled the 500th subject in its ongoing Phase 3 ELAINE-3 clinical trial (NCT05696626) for lasofoxifene in combination with abemaciclib, a CDK4/6 inhibitor, as a targeted therapy for estrogen receptor-positive (ER+), HER2-negative, ESR1-mutated metastatic… Filing
- Aug 14, 2026ResultsReleased financial results. Filing
- Jun 23, 2026VoteReported shareholder vote results. Filing
- May 7, 2026ResultsReleased financial results. Filing
- Mar 31, 2026DealAmended an earlier report. Of Form 8-K, (2) include additional information required by the Staff as a condition of the grant of the waiver, (3) add a copy of the Sermonix License as Exhibit 2.1, (4) update references to the registrant from Athira Pharma, Inc. (or Athira) to LeonaBio, Inc. (or LeonaBio) and (5) make minor… Filing
- Mar 26, 2026ResultsReleased financial results. Filing
- Mar 19, 2026LeadershipThe Company’s board of directors previously approved, subject to stockholder approval, the Company’s 2026 Equity Incentive Plan. Filing
- Jan 9, 2026LeadershipThe Company entered into an Amended and Restated Change in Control and Severance Agreement with Robert Renninger, the Company’s Chief Financial Officer. Filing
- Dec 18, 2025AgreementAmended an earlier report. Athira Pharma, Inc. entered into a securities purchase agreement with a select group of investors, including Commodore Capital LP, TCG Crossover Management LLC, Perceptive Advisors and other accredited investors, one of which is affiliated with a member of the board of directors of the Company… Filing
- Dec 18, 2025AgreementAthira Pharma, Inc. entered into a securities purchase agreement with a select group of investors, including Commodore Capital LP, TCG Crossover Management LLC, Perceptive Advisors and other accredited investors, one of which is affiliated with a member of the board of directors of the Company… Filing
From 8-K reports, which a company must file within 4 business days of an important event. Where a report is about a change such as a new CEO, the sentence is the first one from the report itself, shortened. Each row links to the original filing. Company events this week
LeonaBio financials
Famous investors that hold LONA
3 of the 50 well-known investors we track reported holding LONA in their latest 13F filing. The largest position is Ken Griffin's, worth $308K.
Position size
All holders
| Fund | Quarter | Shares | Value | Of portfolio | Change |
|---|---|---|---|---|---|
| Ken Griffin · Citadel Advisors | Q3 2026 | 86,282 | $308K | 0.0% | +763% |
| Jim Simons · Renaissance Technologies | Q3 2026 | 56,966 | $203K | 0.0% | -26% |
| Israel Englander · Millennium Management | Q3 2026 | 28,620 | $102K | 0.0% | -12% |
From 13F reports: a snapshot at quarter end, filed up to 45 days later. Change compares with the quarter before.
5%+ stakes filed in the last 120 days
Anyone who owns more than 5% of a company must report it on Schedule 13D or 13G. 8 filings named LONA in the last 120 days.
| Filed | Holder | Form | Stake |
|---|---|---|---|
| Nov 13, 2026 | Spruce Street Capital LP | 13G | 4.2% |
| Nov 13, 2026 | Spruce Street Capital LP | 13G | 4.2% |
| Nov 4, 2026 | Great Point Partners, LLC | 13G | 5.0% |
| Nov 4, 2026 | Great Point Partners, LLC | 13G | 5.0% |
| Oct 28, 2026 | Sermonix Pharmaceuticals, Inc. | 13D/A | 25.1% |
| Oct 28, 2026 | Sermonix Pharmaceuticals, Inc. | 13D/A | 25.1% |
| Oct 26, 2026 | Perceptive Advisors LLC | 13D/A | 20.0% |
| Oct 26, 2026 | Perceptive Advisors LLC | 13D/A | 20.0% |
Questions about LeonaBio, Inc. (LONA) stock
Who owns the most LONA stock?
The largest reported owner of LeonaBio, Inc. (LONA) is Perceptive Advisors LLC, with 19.8% of the company. In total, 44 funds and institutions reported holding LONA at the end of Q2 2026, together about 82% of the shares. See the largest owners.
Are LONA insiders buying or selling?
In the last 12 months, LONA insiders reported no open-market purchases and 9 sales worth $93.4K. The latest trade was on Mar 4, 2026. See every trade.
What is the short interest in LONA?
As of Oct 30, 2026, 74,491 LONA shares were sold short, 0.8% of the shares outstanding, down 14.7% from the report before. At the average daily volume of 65,795 shares, buying them all back would take about 1.1 trading days (days to cover). See the history.
Which famous investors hold LONA?
3 of the 50 well-known investors we track reported LONA in their latest 13F filing, including Ken Griffin, Jim Simons, Israel Englander. The largest position is worth $308K. See all holders.
Executive pay
LeonaBio's chief executive was paid a total of $1.4M for the year ended Dec 31, 2025, down 55% from $3.2M the year before. In the last 12 months, LeonaBio's executives and directors bought no stock on the open market and sold $93.4K.
From the pay versus performance table in the company's annual proxy statement (DEF 14A), as the company reported it. If the chief executive changed during the year, the company reports each person separately and this shows one of them.
Source: SEC Form 4 (insiders, filed within 2 business days), 13F (funds, up to 45 days after quarter end) and Schedule 13D/13G filings. Only open-market purchases (code P) and sales (code S) are shown. Data only, not investment advice. How we collect it.